<DOC>
	<DOCNO>NCT00475436</DOCNO>
	<brief_summary>GSK573719 high-affinity specific muscarinic receptor ( mAChR ) antagonist develop daily treatment chronic obstructive pulmonary disease ( COPD ) . The long duration action GSK573719 administer via inhalation animal model support potential use once-daily bronchodilator COPD</brief_summary>
	<brief_title>A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers</brief_title>
	<detailed_description>A single-centre , randomised , double-blind , placebo-controlled , dose-ascending , 3-cohort parallel-group study evaluate safety , tolerability , pharmacodynamics pharmacokinetics GSK573719 administer single dos ( 750µg 1000µg ) repeat dose 14 day ( 250µg-1000µg once-daily ) GSK573719 healthy male female subject</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion criterion : Healthy Caucasian male subject healthy Caucasian female subject nonchildbearing potential Aged 1855 year Nonsmokers Normal spirometry ( FEV1 = 80 % predict , FEV1/FVC = 70 % ) A sign date write informed consent obtain subject The subject capable give informed consent Available complete study Subject BMI within range 18.030.0kg/m2 inclusive Exclusion criterion : Any clinically important abnormality identify screen medical assessment A history breathing problem A mean QTc ( B ) value screen &gt; 450msec , QTc ( B ) 3 screen ECGs within 10 % mean , ECG suitable QT measurements A history elevate rest blood pressure mean blood pressure equal high 140/90 mmHg screen A mean heart rate outside range 4090 bpm screen History use tobacco product within 6 month screen , positive urine cotinine screen Subjects 2D6 poor metabolizer genotype ( Caucasian ) The subject donate unit ( 400ml ) blood within 60 day screening , , intend donate study The subject currently take regular ( course ) medication , whether prescribe The subject take prescription medication within past 2 week prior dose OTC medication within 48 hour prior dose The subject participate study new molecular entity trial within period 3 month prior dose The subject test positive hepatitis C antibody , hepatitis B surface antigen HIV The subject positive prestudy drug screen The subject positive prestudy alcohol screen The subject suspect history alcohol abuse within six month previous screen visit The subject unable use DISKUS The subject know allergy hypersensitivity ipratropium bromide , atropine derivatives The subject know allergy hypersensitivity milk protein excipient lactose monohydrate Subjects might prostatic hypertrophy , bladder outlet obstruction , narrow angle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>muscarinic receptor antagonist</keyword>
	<keyword>GSK573719 ,</keyword>
	<keyword>chronic obstructive pulmonary disease ,</keyword>
</DOC>